Joel Greenblatt Abb Vie Inc. Transaction History

Gotham Asset Management, LLC

$7.56 Billion
Q2 2024

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Abb Vie Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 46,082 shares of ABBV stock, worth $9.24 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

46,082

Previous 61,583 25.17%

Holding current value

$9.24 Million

Previous $11.2 Million 29.53%

% of portfolio

0.1%

Previous 0.17%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$154.79 - $180.76 $2.4 Million - $2.8 Million	-15,501 Reduced 25.17%	46,082 $7.9 Million
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $2.74 Million - $3.13 Million	17,166 Added 38.65%	61,583 $11.2 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $4.01 Million - $4.52 Million	-29,168 Reduced 39.64%	44,417 $6.88 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $2.51 Million - $2.91 Million	18,800 Added 34.32%	73,585 $11 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $3.78 Million - $4.7 Million	28,499 Added 108.42%	54,785 $7.38 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $825,144 - $950,277	-5,706 Reduced 17.84%	26,286 $4.19 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $3.03 Million - $3.64 Million	-21,934 Reduced 40.67%	31,992 $5.17 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $226,546 - $259,833	1,688 Added 3.23%	53,926 $7.24 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $634,152 - $806,215	4,608 Added 9.67%	52,238 $8 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $1.18 Million - $1.47 Million	-8,962 Reduced 15.84%	47,630 $7.72 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $5.23 Million - $6.62 Million	-48,702 Reduced 46.25%	56,592 $7.66 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $5.06 Million - $5.75 Million	47,567 Added 82.4%	105,294 $11.4 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $1.07 Million - $1.19 Million	-10,187 Reduced 15.0%	57,727 $6.5 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $819,013 - $901,635	8,006 Added 13.36%	67,914 $7.35 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $2.03 Million - $2.74 Million	25,174 Added 72.48%	59,908 $6.42 Million
Q3 2020 Nov 16, 2020	SELL	$85.91 - $100.83 $14.2 Million - $16.6 Million	-164,931 Reduced 82.6%	34,734 $3.04 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $4.95 Million - $6.62 Million	67,425 Added 50.99%	199,665 $19.6 Million
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $3.44 Million - $5.22 Million	-53,384 Reduced 28.76%	132,240 $10.1 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $2.32 Million - $2.9 Million	-32,101 Reduced 14.74%	185,624 $16.4 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $12 Million - $14.4 Million	-190,784 Reduced 46.7%	217,725 $16.5 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $2.76 Million - $3.53 Million	42,056 Added 11.48%	408,509 $29.7 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $4.87 Million - $5.74 Million	63,196 Added 20.84%	366,453 $29.5 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $1.79 Million - $2.21 Million	-22,979 Reduced 7.04%	303,257 $28 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $5.65 Million - $6.28 Million	-63,563 Reduced 16.31%	326,236 $30.9 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $4.94 Million - $5.84 Million	-55,015 Reduced 12.37%	389,799 $36.1 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $18.9 Million - $25.3 Million	205,570 Added 85.92%	444,814 $42.1 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $14.3 Million - $15.7 Million	-159,593 Reduced 40.01%	239,244 $23.1 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $27.9 Million - $35.6 Million	398,837	398,837 $35.4 Million

Others Institutions Holding ABBV

# of Institutions

3,771

Shares Held

1.28B

Call Options Held

13M

Put Options Held

9.83M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $354B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account